Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death in patients with mildly reduced or preserved ejection fraction.
Does dapagliflozin reduce the combined risk of worsening heart failure or cardiovascular death in patients with heart failure and a mildly reduced or preserved ejection fraction?
Patients with heart failure and a mildly reduced or preserved ejection fraction
Dapagliflozin
Combined risk of worsening heart failure or cardiovascular deathcomposite
Dapagliflozin reduces the composite risk of worsening heart failure or cardiovascular death in patients with mildly reduced or preserved ejection fraction.
Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Scott D. Solomon
John J.V. McMurray
Brian Claggett
New England Journal of Medicine
Harvard University
Yale University
University of Toronto
Building similarity graph...
Analyzing shared references across papers
Loading...
Solomon et al. (Sat,) reported a other. Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death in patients with mildly reduced or preserved ejection fraction.
www.synapsesocial.com/papers/696511723516c4690044ecdb — DOI: https://doi.org/10.1056/nejmoa2206286